1297. Tigecycline Susceptibility Analysis among E. coli and Klebsiella spp., Including ESBL-Producing Isolates, in Europe; TEST Program Data from Europe (2008-2012)
Session: Poster Abstract Session: Below the Diaphragm
Saturday, October 5, 2013
Room: The Moscone Center: Poster Hall C
  • IDSA 1297.pdf (1.0 MB)
  • Background: The Tigecycline Evaluation Surveillance Trial (TEST) monitors the activity of tigecycline and comparators against multiple pathogens collected worldwide. This report is an analysis of tigecycline susceptibility of E. coli and Klebsiella spp. collected from Europe between 2008 and 2012.

    Methods: The total isolate numbers for 2008 to 2012 were 1,815 E. coli (ESBL), 8203 E. coli (non ESBL),  85 K. oxytoca (ESBL), 2,309 K. oxytoca (non ESBL), 1,837 K. pneumoniae (ESBL) & 5,573 K. pneumoniae (non ESBL).  MICs were performed as specified by CLSI at each site using prepared broth microdilution panels and interpreted according to CLSI guidelines (tigecycline using FDA breakpoints).  Differences in % susceptibility (%S) were evaluated for statistical significance with the Cochrane Armitage Test (significant where trend p-value <0.05).

    Results: %S results for tigecycline between 2008 and 2012 are shown below.


    Conclusion: TGC showed excellent in vitro activity >90% %S against E. coli and Klebsiella spp., with or without ESBL and no significant trend of changed %S was observed between 2008 & 2012.  These data confirm the continued utility of tigecycline against drug-resistant bacteria.


    Samuel Bouchillon, MD1, Ian Morrissey, PhD2, Stephen Hawser, PhD3, Meredith Hackel, PhD1, Daryl Hoban, PhD1, Douglas Biedenbach, BS4 and Jack Johnson, MS, MBA1, (1)Ihma, Inc., Schaumburg, IL, (2)Ihma, Schaumburg, IL, (3)Ihma Europe SÓrl, Epalinges, Switzerland, (4)Ihma Inc., Schaumburg, IL


    S. Bouchillon, None

    I. Morrissey, None

    S. Hawser, None

    M. Hackel, None

    D. Hoban, None

    D. Biedenbach, None

    J. Johnson, None

    See more of: Below the Diaphragm
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.